August 23, 2022
AABB recently released a summary of the Centers for Medicare and Medicaid Services (CMS)’s proposed rule that would update Medicare payment rates and policies under the hospital outpatient prospective payment system (OPPS) and the ambulatory surgical center payment system for calendar year (CY) 2023. The proposed rule was published in the Federal Register on July 26.
The summary highlights proposed changes that are of interest to the blood and biotherapies community: slight payment increases for most blood products; the creation of a new HCPCS code (C9507) for COVID-19 convalescent plasma (CCP) furnished in the outpatient setting; increased payment rates for most transfusion and laboratory services covered by the OPPS; and changes to the HCPCS code for axicabtagene ciloleucel (Yescarta, Kite Pharma), a type of chimeric antigen receptor (CAR) T-cell therapy. The document also provides tables that summarize the proposed payment rates for these products and services.
AABB will be submitting comments to CMS on the proposed rule and encourages members to share questions or feedback for consideration with AABB’s Advocacy team.